GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about General Updates
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals held its 100th AGM on June 27, 2025, via video conferencing, where all six resolutions were approved with overwhelming shareholder support. Key outcomes include confirmation of interim dividend and declaration of a final dividend of Rs 42 per equity share for FY ending March 31, 2025, adoption of audited financial statements, and re-appointment of Mr. Juby Chandy as Director and Dr. Sunita Maheshwari as Independent Director. Parikh & Associates was appointed as Secretarial Auditor, and the remuneration of the Cost Auditor was ratified. Voting results showed near-unanimous approval across all resolutions, ranging from 98.30% to 100% in favour, with only minor dissent on the independent director re-appointment (1.70% against). A total of 81 shareholders attended through VC (4 promoter group representatives and 77 public shareholders).
Positive for shareholders as the Rs 42 final dividend is confirmed, and strong approval across all resolutions (above 98%) signals solid shareholder confidence in management. No contentious issues emerged, suggesting stable governance and minimal near-term risks.